You are here

FDA Delays Decision on Inhaled Insulin Product Afrezza

Advisory panel recommended approval

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Afrezza by 3 months to July 15, 2014, to provide time for a full review of information submitted in response to the FDA's requests.

According to the product’s developer (Mannkind Corp.), Afrezza is a rapid-acting mealtime insulin therapy developed to improve glycemic control in adult patients with type 1 or type 2 diabetes. It is a drug–device combination product consisting of Afrezza inhalation powder delivered using a small inhaler.

Administered at the start of a meal, Afrezza inhalation powder dissolves immediately upon inhalation to the deep lung and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 15 minutes of administration, compared with 45 to 90 minutes for injected rapid-acting insulin analogs and 90 to 150 minutes for injected regular human insulin.

The FDA’s delay in reviewing Afrezza comes less than a week after an advisory panel recommended approving the treatment, but said longer-term studies would be required to gauge the risk of lung cancer and other potential side effects.

If approved, Afrezza would be the first inhaled insulin treatment available in the U.S. since 2006.

Sources: Mannkind Corp.; April 7, 2014; and Reuters; April 7, 2014.

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers